Clinical Trial Results: Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pembrolizumab plus lenvatinib for brain metastases from melanoma or renal cell carcinoma; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Melanoma
• Renal Cell Carcinoma

Drugs mentioned

• Lenvatinib (lenvatinib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Yale University | Conditions: Melanoma, Renal Cell Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2026-06-04